Bliss GVS Pharma Limited

BSE:506197 Stock Report

Market Cap: ₹17.0b

Bliss GVS Pharma Past Earnings Performance

Past criteria checks 0/6

Bliss GVS Pharma's earnings have been declining at an average annual rate of -6.3%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 2.9% per year. Bliss GVS Pharma's return on equity is 6.9%, and it has net margins of 7.9%.

Key information

-6.3%

Earnings growth rate

-6.6%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate2.9%
Return on equity6.9%
Net Margin7.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Bliss GVS Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:506197 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248,0026341,4660
30 Jun 247,9448151,4240
31 Mar 247,7027551,3940
31 Dec 237,5698791,2340
30 Sep 237,6198831,2130
30 Jun 237,2245981,1900
31 Mar 237,5167091,1600
31 Dec 227,3398711,2840
30 Sep 227,444911,2560
30 Jun 227,6801651,2350
31 Mar 227,4751501,0450
31 Dec 217,124178960
30 Sep 216,6027738760
30 Jun 216,1587666980
31 Mar 215,7726858270
31 Dec 205,6507107630
30 Sep 205,4876927300
30 Jun 206,0737975820
31 Mar 206,8939736840
31 Dec 198,1361,0668350
30 Sep 198,8611,0878050
30 Jun 199,0441,1925250
31 Mar 198,9861,2377480
31 Dec 183,7886232340
30 Sep 183,5435433000
30 Jun 183,5214693690
31 Mar 183,7202974320
31 Dec 179,0631,0981,6690
30 Sep 179,4231,0531,6590
30 Jun 178,8438601,6270
31 Mar 174,0335096540
31 Dec 166,7116649440
30 Sep 165,7557428530
30 Jun 165,9118363700
31 Mar 165,4698257820
31 Mar 154,0715997640
31 Mar 143,4464108280

Quality Earnings: 506197 has a large one-off loss of ₹287.4M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 506197's current net profit margins (7.9%) are lower than last year (11.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 506197's earnings have declined by 6.3% per year over the past 5 years.

Accelerating Growth: 506197's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 506197 had negative earnings growth (-28.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.5%).

Return on Equity

High ROE: 506197's Return on Equity (6.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 21:12
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bliss GVS Pharma Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kameswari V. S. ChavaliFirstCall Research
Anil BurraFirstCall Research